🇺🇸 Palliative Chemotherapy in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 10
Most-reported reactions
- Alanine Aminotransferase Increased — 1 report (10%)
- Aspartate Aminotransferase Increased — 1 report (10%)
- Disease Progression — 1 report (10%)
- Febrile Neutropenia — 1 report (10%)
- Immunosuppression — 1 report (10%)
- Leukopenia — 1 report (10%)
- Lymphopenia — 1 report (10%)
- Neutropenia — 1 report (10%)
- Pertussis — 1 report (10%)
- Pneumocystis Jiroveci Pneumonia — 1 report (10%)
Other Oncology approved in United States
Frequently asked questions
Is Palliative Chemotherapy approved in United States?
Palliative Chemotherapy does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Palliative Chemotherapy in United States?
Sun Yat-sen University is the originator. The local marketing authorisation holder may differ — check the official source linked above.